Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.
Subklewe M, Magno G, Gebhardt C, Bücklein V, Szelinski F, Arévalo HJR, Hänel G, Dörner T, Zugmaier G, von Bergwelt-Baildon M, Skapenko A, Schulze-Koops H. Subklewe M, et al. Among authors: gebhardt c. Eur J Cancer. 2024 Apr 22;204:114071. doi: 10.1016/j.ejca.2024.114071. Online ahead of print. Eur J Cancer. 2024. PMID: 38691878 Free article.
Reply to: On the statistical foundation of a recent single molecule FRET benchmark.
Götz M, Barth A, Bohr SS, Börner R, Chen J, Cordes T, Erie DA, Gebhardt C, Hadzic MCAS, Hamilton GL, Hatzakis NS, Hugel T, Kisley L, Lamb DC, de Lannoy C, Mahn C, Dunukara D, de Ridder D, Sanabria H, Schimpf J, Seidel CAM, Sigel RKO, Sletfjerding MB, Thomsen J, Vollmar L, Wanninger S, Weninger KR, Xu P, Schmid S. Götz M, et al. Among authors: gebhardt c. Nat Commun. 2024 Apr 30;15(1):3626. doi: 10.1038/s41467-024-47734-2. Nat Commun. 2024. PMID: 38688911 Free PMC article. No abstract available.
Erfolgreiche Behandlung eines Checkpoint‐Inhibitor‐assoziierten bullösen Pemphigoids mit Dupilumab bei Angiosarkom: Successful treatment of checkpoint inhibitor‐associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.
Hansen I, Gebhardt C, Booken N, Schneider SW. Hansen I, et al. Among authors: gebhardt c. J Dtsch Dermatol Ges. 2024 Apr;22(4):587-590. doi: 10.1111/ddg.15340_g. J Dtsch Dermatol Ges. 2024. PMID: 38574016 German. No abstract available.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. Among authors: gebhardt c. EClinicalMedicine. 2024 Mar 27;71:102564. doi: 10.1016/j.eclinm.2024.102564. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38572079 Free PMC article. No abstract available.
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, Smit DJ, Hansen I, Abeck F, Schadendorf D, Eggermont A, Puig S, Hauschild A, Gebhardt C. Kött J, et al. Among authors: gebhardt c. Eur J Cancer. 2024 May;202:113989. doi: 10.1016/j.ejca.2024.113989. Epub 2024 Mar 8. Eur J Cancer. 2024. PMID: 38518535 Free article. Review.
491 results